EXELIXIS INC
For the period ended Dec 29, 2023. Filed Feb 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 6, 2024
EXEL$70.58-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income | $207,765 | $182,282 | $231,063 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation | 25,717 | 20,875 | 13,630 |
| Stock-based compensation | 106,345 | 107,574 | 119,820 |
| Non-cash lease expense | 28,976 | 18,315 | 5,332 |
| Deferred taxes | (133,209) | (60,358) | 46,529 |
| Acquired in-process research and development technology | 128,500 | 107,250 | 14,000 |
| Other, net | (16,797) | (525) | 9,443 |
| Changes in operating assets and liabilities: | |||
| Trade receivables, net | (22,623) | 66,849 | (122,324) |
| Inventory | (12,977) | (11,683) | (13,209) |
| Prepaid expenses and other assets | (29,824) | (28,259) | (39,875) |
| Deferred revenue | (3,140) | (2,483) | 11,008 |
| Accrued collaboration liabilities | 1,345 | (63,065) | 70,297 |
| Accounts payable and other liabilities | 53,246 | 25,842 | 55,090 |
| Net cash provided by operating activities | 333,324 | 362,614 | 400,804 |
| Cash flows from investing activities: | |||
| Purchases of property, equipment and other | (40,469) | (27,706) | (54,225) |
| Acquired in-process research and development technology | (122,500) | (110,750) | (10,000) |
| Purchases of investments | (902,468) | (1,450,716) | (1,357,168) |
| Proceeds from maturities and sales of investments | 1,038,482 | 1,064,758 | 1,378,509 |
| Net cash used in investing activities | (26,955) | (524,414) | (42,884) |
| Cash flows from financing activities: | |||
| Payments for repurchases of common stock | (550,378) | — | — |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 33,448 | 23,886 | 24,307 |
| Taxes paid related to net share settlement of equity awards | (29,122) | (23,300) | (39,108) |
| Net cash provided by (used in) financing activities | (546,052) | 586 | (14,801) |
| Net increase (decrease) in cash and cash equivalents | (239,683) | (161,214) | 343,119 |
| Cash and cash equivalents at beginning of period | 502,677 | 663,891 | 320,772 |
| Cash and cash equivalents at end of period | $262,994 | $502,677 | $663,891 |
| Supplemental cash flow disclosures: | |||
| Cash paid for taxes | $185,658 | $127,870 | $12,960 |
| Non-cash operating activities: | |||
| Right-of-use assets obtained in exchange for lease obligations | $16,623 | $155,935 | $4,893 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.